Potent CXCR2 antagonist (IC50
= 7.7 nM). Exhibits 285-fold selectivity for CXCR2 over CXCR1. Reduces leukocyte numbers in synovial fluid in acute and chronic rabbit arthritis models. Also reduces synovial fluid eicosanoid and cytokine levels in a rabbit chronic arthritis model. Inhibits proliferation of AML cells lines in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit.
Podolin et al.
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke et al.